Kiromic BioPharma, Inc.
KRBP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $3 | $2 | $0 |
| Gross Profit | $0 | -$3 | -$2 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $10 | $14 | $11 |
| G&A Expenses | $9 | $10 | $17 | $14 |
| SG&A Expenses | $9 | $8 | $17 | $14 |
| Sales & Mktg Exp. | $0 | -$3 | $0 | $0 |
| Other Operating Expenses | $8 | $0 | $0 | $0 |
| Operating Expenses | $24 | $17 | $31 | $25 |
| Operating Income | -$24 | -$20 | -$31 | -$26 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$3 | -$1 | -$4 | $0 |
| Pre-Tax Income | -$27 | -$21 | -$35 | -$26 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$27 | -$21 | -$38 | -$26 |
| % Margin | – | – | – | – |
| EPS | -1.03 | -21.41 | -70.12 | -67.4 |
| % Growth | 95.2% | 69.5% | -4% | – |
| EPS Diluted | -1.03 | -21.41 | -70.12 | -67.4 |
| Weighted Avg Shares Out | 26 | 33 | 16 | 11 |
| Weighted Avg Shares Out Dil | 26 | 33 | 16 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$4 | -$2 | $0 | $0 |
| Depreciation & Amortization | $7 | $3 | $2 | $0 |
| EBITDA | -$24 | -$16 | -$32 | -$25 |
| % Margin | – | – | – | – |